Identification of novel immunogenic human leukocyte antigen-A*2402- binding epitopes of human papillomavirus type 16 E7 for immunotherapy against human cervical cancer

Cancer

Volumn 118, Issue 8, 2012, Pages 2173-2183

  Jang, Sunphil ^a   Kim, Young Tae ^a   Chung, Hye Won ^a   Lee, Kyoung Ryul ^b   Lim, Jong Baeck ^a   Lee, Kyungwon ^a  

^a Yonsei University   (South Korea)

^b Seoul Medical Science Institute   (South Korea)

Author keywords

cervical cancer; epitopes; HLA A24; HPV 16 E7; immunotherapy

Indexed keywords

CISPLATIN; EPITOPE; FAS ANTIGEN; GAMMA INTERFERON; HLA A ANTIGEN; HUMAN LEUKOCYTE ANTIGEN A 2402; PROTEIN E7; PROTEIN E7[61-69]; PROTEIN E7[67-76]; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CELL ASSAY; CELL ISOLATION; CONTROLLED STUDY; CYTOTOXIC LYMPHOCYTE; CYTOTOXICITY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; IN VITRO STUDY; IN VIVO STUDY; INTERFERON PRODUCTION; LYMPHOCYTIC INFILTRATION; MONOTHERAPY; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCREENING; TUMOR XENOGRAFT; UTERINE CERVIX CANCER;

CISPLATIN; EPITOPES, T-LYMPHOCYTE; FEMALE; HLA-A24 ANTIGEN; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNOTHERAPY, ADOPTIVE; PAPILLOMAVIRUS E7 PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; UTERINE CERVICAL NEOPLASMS;

EID: 84859630234     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26468     Document Type: Article

References (30)

1. Pisani P, Bray F, Parkin DM,. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer. 2002; 97: 72-81.
2. zur Hausen H,. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002; 2: 342-350.
3. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189: 12-19.
4. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003; 348: 518-527.
5. Kim JJ,. Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis. 2010; 10: 845-852.
6. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007; 365: 1928-1943.
7. Harper DM,. Impact of vaccination with Cervarix (trade marker) on subsequent HPV-16/18 infection and cervical disease in women 15-25 years of age. Gynecol Oncol. 2008; 110: S11-S17.
8. Huang CF, Monie A, Weng WH, Wu TC,. DNA vaccine for cervical cancer. Am J Transl Res. 2010; 2: 75-87.
9. Bosch FX, Lorinez A, Munoz N, Meijer CJ, Shah KV,. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002; 55: 244-265.
10. Frazer IH, Cox JT, Mayeaux EJ Jr, et al. Advances in prevention of cervical cancer and other human papillomavirus-related diseases. Pediat Infect Dis J. 2006; 25: S65-S81.
11. Cannistra SA, Niloff JM,. Cancer of the uterine cervix. N Engl J Med. 1996; 334: 1030-1038.
12. Aiba S, Rokugo M, Tagami H,. Immunohistologic analysis of the phenomenon of spontaneous regression of numerous flat warts. Cancer. 1986; 58: 1246-1251.
13. Coleman N, Birley HD, Renton AM, et al. Immunological events in regressing genital warts. Am J Clin Pathol. 1994; 102: 768-774.
14. Hopfl R, Heim K, Christensen N, et al. Spontaneous regression of CIN and delayed-type hypersensitivity to HPV-16 oncoprotein E7. Lancet. 2000; 356: 1985-1986.
15. Ressing ME, Sette A, Brandt RM, et al. Human CTL epitopes encoded by human papillomavirus type 16, E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol. 1995; 154: 5934-5943.
16. Morishima S, Akatsuka Y, Nawa A, et al. Identification of an HLA-A24-restricted cytotoxic T lymphocyte epitope form human papillomavirus type-16 E6: the combined effects of bortezomib and interferon-gamma on the presentation of a cryptic epitope. Int J Cancer. 2007; 120: 594-604.
17. Lim JB, Provenzano M, Kwon OH, et al. Identification of HLA-A33-restricted CMV pp65 epitopes as common targets for CD8(+) CMV-specific cytotoxic T lymphocytes. Exp Hematol. 2006; 34: 296-307.
18. Lim JB, Kim HO, Jeong SH, et al. Identification of HLA-A*2402- restricted HCMV immediate early-1 (IE-1) epitopes as targets for CD8+ HCMV-specific cytotoxic T lymphocytes. J Transl Med. 2009; 7: 72-82.
19. Friedl F, Kimura I, Osato T, Ito Y,. Studies on a new human cell line (SiHa) derived from carcinoma of uterus. I. Its establishment and morphology. Proc Soc Exp Biol Med. 1970; 135: 543-545.
20. Kuzushima K, Kimura H, Hoshino Y, et al. Longitudinal dynamics of Epstein-Barr virus-specific cytotoxic T lymphocytes during posttransplant lymphoproliferative disorder. J Infect Dis. 2000; 182: 937-940.
21. Bao L, Dunham K, Stamer M, Mulieri KM, Lucas KG,. Expansion of cytomegalovirus pp65 and IE-1 specific cytotoxic T lymphocytes for cytomegalovirus-specific immunotherapy following allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2008; 14: 1156-1162.
22. Kenter GG, Welters MJ, Valentijn AR, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med. 2009; 361: 1838-1847.
23. Monie A, Tsen SW, Wu T-C,. Therapeutic HPV DNA vaccines. Expert Rev Vaccines. 2009; 8: 1221-1235.
24. Schiller JT, Castellsague X, Villa LL, Hildesheim A,. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine. 2008; 19: 53-61.
25. Kubo RT, Sette A, Grey HM, et al. Definition of specific peptide motifs for 4 major HLA-A alleles. J Immunol. 1994; 152: 3913-3924.
26. Patel S, Chiplunkar S,. Host immune responses to cervical cancer. Curr Opin Obstet Gynecol. 2009; 21: 54-59.
27. Kim TY, Myoung HJ, Kim JH, et al. Both E7 and CpG-ODN are required for protective immunity against challenge with human papillomavirus 16 (E6/E7)-immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection. Cancer Res. 2002; 62: 7234-7240.
28. Tseng CW, Hung CF, Alvarez RD, et al. Pretreatment with cisplatin enhances E7-specific Cd8+ T-cell-mediated antitumor immunity induced by DNA vaccination. Clin Cancer Res. 2008; 14: 3185-3192.
29. Bae SH, Park YJ, Park JB, Choi YS, Kim MS, Sin JI,. Therapeutic synergy of human papillomavirus E7 subunit vaccines plus cisplatin in an animal tumor model: causal involvement of increased sensitivity cisplatin-treated tumors to CTL-mediated killing in therapeutic synergy. Clin Cancer Res. 2007; 13: 341-349.
30. Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S,. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol. 2007; 179: 977-983.